Donations
Donations

News from the Swiss Cancer Institute

With regular training programs, events and symposia, we promote collaboration and further training of researchers in clinical cancer research.

24. September 2026

2026 Press Conference: Clinical Research in Switzerland Under Pressure

The number of clinical trials in Switzerland is declining. This has implications not only for patients, who are consequently less likely to gain early access to innovative therapies, but also for Switzerland as a business hub and for the research ecosystem.

14. September 2026

Article from info@onco-suisse: Rising Costs in Oncology

Spending on cancer care is rising and is increasingly becoming a focus of health policy discussions. The prices of new drugs and therapies are often viewed as key cost drivers. However, the situation is more complex: population growth, an aging population, and medical advances also contribute to rising costs.

09. September 2026

Clinical Cancer Research in Switzerland Under Pressure

A recent report by SRF 10 vor 10 shows that Switzerland and Europe are increasingly falling behind Asia in the field of clinical cancer research. This trend affects both the research community and patients.

17. August 2026

Partnership Between the Philas Foundation and the Swiss Cancer Institute

The Swiss Cancer Institute and the Philas Foundation are entering into a long-term partnership to specifically advance gender-specific medicine in oncology. Together, we are committed to gender-sensitive and precision cancer medicine that promotes equal opportunities and improves the quality of life for patients.

09. July 2026

Interview: Lorenz Tanner on the SCI Patient Advisory Board and patient-centered research

Universimed spoke with Lorenz Tanner, a member of the SCI Patient Advisory Board, about the importance of patient involvement and the role patients play in clinical cancer research.

Lorenz Tanner

22. June 2026

Annual Report 2025 Online: Research, Progress and Transformation

Discover the key research projects, milestones and developments that shaped the Swiss Cancer Institute in 2025.

19. June 2026

Swiss Cancer Institute Awards 2026

SCI and Partners Recognize Cancer Research Projects

19. June 2026

Swiss Cancer Institute/Astellas & AstraZeneca Translational GU Oncology Research Award

The Swiss Cancer Institute, together with Astellas and AstraZeneca, presented the 2026 Translational GU Oncology Research Award to Victor Le Gall of the University of Basel for his research project on immune responses in muscle-invasive bladder cancer.

17. June 2026

Südostschweiz reports on the SAKK 96/12 REDUSE study

An international study led by Prof. Dr. med. Roger von Moos shows that administering denosumab less frequently, while maintaining the same level of efficacy, can reduce the burden on patients.

17. June 2026

ASCO 2026: SAKK 06/19 Shows Promising Results in Bladder Cancer

Results presented at ASCO 2026 demonstrate high response rates with a novel combination of recombinant BCG and perioperative chemoimmunotherapy in muscle-invasive bladder cancer.